Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
65 hedge funds and large institutions have $21.3M invested in Seelos Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 13 increasing their positions, 18 reducing their positions, and 26 closing their positions.
911% more call options, than puts
Call options by funds: $799K | Put options by funds: $79K
16% less funds holding
Funds holding: 77 → 65 (-12)
28% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 18
35% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 26
35% less capital invested
Capital invested by funds: $33M → $21.3M (-$11.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$930K |
| 2 |
UIC
Uniplan Investment Counsel
Milwaukee,
Wisconsin
|
+$636K |
| 3 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
+$576K |
| 4 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$435K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$425K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.06M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$1.11M |
| 3 |
State Street
Boston,
Massachusetts
|
-$969K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$492K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$466K |
SEEL Hedge Fund Activity: Q2 2022 in Review
65 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q2 2022, worth a combined $21.3M — down 35% from $33M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of SEEL and 17 opened new positions — a net loss of 9 holders — while 18 trimmed existing stakes and 13 added.
The largest buyer was Millennium Management, adding an estimated $930K. The largest seller was BlackRock, cutting an estimated $3.06M.
- 65 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q2 2022, down from 77 in Q1 2022.
- Funds reported $21.3M of Seelos Therapeutics, Inc. Common Stock stock for Q2 2022, down 35% quarter-over-quarter.
- 17 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q2 2022 and 26 closed out, a net change of -9 holders.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q2 2022 was Millennium Management, an estimated $930K added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q2 2022 was BlackRock, an estimated $3.06M sold.
Based on aggregated 13F filings for Q2 2022.